Literature DB >> 11716917

Effect of infliximab on threatening panuveitis in Behçet's disease.

S Muñoz-Fernández, V Hidalgo, J Fernández-Melón, A Schlincker, E Martín-Mola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11716917     DOI： 10.1016/S0140-6736(01)06677-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  19 in total

1.  Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.

Authors:  Atsushi Yoshida; Toshikatsu Kaburaki; Kimiko Okinaga; Mitsuko Takamoto; Hidetoshi Kawashima; Yujiro Fujino
Journal:  Jpn J Ophthalmol       Date:  2012-10-02       Impact factor: 2.447

Review 2.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

Review 3.  Behçet's disease: a new target for anti-tumour necrosis factor treatment.

Authors:  P P Sfikakis
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

4.  Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab.

Authors:  Daiju Iwata; Kenichi Namba; Kazuomi Mizuuchi; Nobuyoshi Kitaichi; Satoru Kase; Yuko Takemoto; Shigeaki Ohno; Susumu Ishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-11       Impact factor: 3.117

5.  Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.

Authors:  S Guignard; L Gossec; C Salliot; A Ruyssen-Witrand; M Luc; M Duclos; M Dougados
Journal:  Ann Rheum Dis       Date:  2006-08-10       Impact factor: 19.103

6.  Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions.

Authors:  Alfredo Adán; Victoria Hernandez; Santiago Ortiz; Juan Jose Molina; Laura Pelegrin; Gerard Espinosa; Raimon Sanmartí
Journal:  Int Ophthalmol       Date:  2010-05-20       Impact factor: 2.031

7.  Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.

Authors:  Massimo Accorinti; Maria Pia Pirraglia; Maria Pia Paroli; Roberta Priori; Fabrizio Conti; Paola Pivetti-Pezzi
Journal:  Jpn J Ophthalmol       Date:  2007-06-07       Impact factor: 2.447

8.  Role of IL-22- and TNF-α-producing Th22 cells in uveitis patients with Behcet's disease.

Authors:  Sunao Sugita; Yuko Kawazoe; Ayano Imai; Tatsushi Kawaguchi; Shintaro Horie; Hiroshi Keino; Masayo Takahashi; Manabu Mochizuki
Journal:  J Immunol       Date:  2013-04-29       Impact factor: 5.422

9.  Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome.

Authors:  Hiroaki Tanaka; Naomi Shimizu; Emi Tougasaki; Chika Kawajiri; Shinichiro Hashimoto; Yusuke Takeda; Shio Sakai; Masahiro Takeuchi; Chikako Ohwada; Emiko Sakaida; Toshiyuki Takagi; Chiaki Nakaseko
Journal:  Int J Hematol       Date:  2013-03-22       Impact factor: 2.490

10.  Analysis of Th Cell-related Cytokine Production in Behçet Disease Patients with Uveitis Before and After Infliximab Treatment.

Authors:  Masaru Takeuchi; Yoko Karasawa; Kohzou Harimoto; Atsushi Tanaka; Masaki Shibata; Tomohito Sato; Rachel R Caspi; Masataka Ito
Journal:  Ocul Immunol Inflamm       Date:  2016-04-12       Impact factor: 3.070
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.